Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA
Auteurs principaux: Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Pencina, Michael, Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2018
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583576/
https://ncbi.nlm.nih.gov/pubmed/30418475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.18269
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires